Stock Financial Ratios


ADRO / Aduro Biotech, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price8.80
Volume373,900.00
Market Cap ($M)653.96
Enterprise Value ($M)510.57
Book Value ($M)227.22
Book Value / Share3.48
Price / Book2.55
NCAV ($M)407.98
NCAV / Share6.26
Price / NCAV1.54
Income Statement (mra) ($M)
Revenue50.68
EBITDA-71.86
Net Income-91.15
Balance Sheet (mrq) ($M)
Cash & Equivalents159.04
Cash / Share2.44
Assets465.13
Liabilities208.72
Quick Ratio11.58
Current Ratio11.58
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.40
Return on Assets (ROA)-0.21
Return on Equity (ROE)-0.40
Identifiers and Descriptors
CUSIP00739L101
Central Index Key (CIK)1435049
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
00739L901
00739L951
Share Statistics
Common Shares Outstanding (M)77.30
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Property Plant And Equipment Net Per Share0.43
Assets Current Per Share5.58
Accumulated Depreciation And Depletion Per Share0.10
Assets Per Share7.13
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Liabilities Per Share3.20
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Additional Paid In Capital Per Share7.86
Cash And Equivalents Per Share2.44
Cash Per Share2.44
Goodwill Per Share0.13
Assets Other Non Current Per Share0.01
Inventory Work In Progress Per Share0.00
Liabilities Current Per Share0.53
Property Plant And Equipment Per Share0.43
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Property Plant And Equipment Gross Per Share0.53
Liabilities Other Non Current Per Share0.02
Debt Per Share0.00
Inventory Per Share0.00
Deferred Income Tax Liabilities Per Share0.10
Equity Per Share3.93
Liabilities And Stock Equity Per Share7.13
Intangibles Per Share0.47
Accounts Receivable Per Share0.02
Retained Earnings Per Share-3.95

Related News Stories

BRIEF-Aduro Biotech ‍announces data from preclinical studies with ADU-1604

2017-11-10 reuters
* Aduro Biotech Inc - ‍announced data from preclinical studies with ADU-1604, company’s humanized anti-CTLA-4 monoclonal antibody​ (8-0)

Merck: A Slow And Steady Dividend Grower, But Do Better Alternatives Exist?

2017-11-05 seekingalpha
Blue chip drug makers such as Merck (NYSE:MRK) have historically been very popular with income investors because of their defensive nature, meaning that drug demand isn't really affected by economic downturns. (57-0)

9 Speculative Analyst Stocks With Projected Upside of 50% to 200%

2017-11-04 247wallst
Investors have seen the markets rise and rise in 2017, with new all-time highs almost weekly, and this bull market is now nearing nine years old. The Dow has now run above 23,500, and the S&P 500 is now well over 2,500. Even the Nasdaq is nearing 7,000 for the first time. The business climate is firm, and there are some positive growth developments driving the continued excitement for stocks. Many investors are still looking for new ideas to generate gains or income ahead. (145-3)

Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss

2017-11-01 zacks
Aduro BioTech, Inc. (ADRO - Free Report) reported third-quarter 2017 loss of 33 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 54 cents per share. (91-0)

Celgene Down on Discontinued Crohn's Disease Drug Study

2017-10-21 zacks
Shares of Celgene Corporation (CELG - Free Report) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn’s disease and the extension trial, SUSTAIN (CD-004) will be discontinued. (157-0)

CUSIP: 00739L101